The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma

NCT07506447 | Completed

• 1 other identifier: XLan-251264
• Study Type: observational
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

This project will target patients with histopathologically diagnosed mucosal melanoma using \[¹⁸F\]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of \[¹⁸F\]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative \[¹⁸F\]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.

Conditions

FDG PET; Mucosal Melanoma

Outcome Measures

Primary Outcomes (2)

• Overall survival

  Overall survival (OS) is defined as the time elapsed from the date of the ¹⁸F-FDG PET/CT examination to the date of death.

  Up to 4 years

• Progression-free survival

  Progression-free survival (PFS) is defined as the time from the date of \[18F\]FDG PET/CT imaging to the earliest date of disease progression, recurrence, or death.

  Up to 4 years

Study Arms (1)

Mucosal Melanoma Cohort

Retrospective cohort of mucosal melanoma patients who underwent \[18F\]FDG PET/CT for prognostic evaluation.

Other: Telephone follow-up

Interventions

Telephone follow-up OTHER

Telephone follow-up

Mucosal Melanoma Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

We reviewed the electronic medical record and imaging data of patients with pathologically confirmed mucosal melanoma who underwent \[18F\]FDG PET/CT imaging at the PET Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 1, 2021 and June 1, 2024.

You may qualify if:

• Patients with histopathologically confirmed mucosal melanoma.

You may not qualify if:

• Having another primary malignancy (other than mucosal melanoma).
• Being lost to follow-up.
• Being under 18 years of age.
• Being pregnant or breastfeeding.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

Study Sites (1)

Wuhan Union Hospital

Wuhan, Hubei, 430022, China

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2026
• First Posted: April 1, 2026
• Study Start: January 1, 2021
• Primary Completion: May 8, 2025
• Study Completion: March 13, 2026
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

CN (1)